Coherus Biosciences | CHRS - Créances Commerciales





Créances Commerciales Changement Date
AbbVie USD 12.59B 180M 2025-12
Acadia Pharmaceuticals USD 148.23M 8.79M 2025-12
Akebia Therapeutics USD 47.03M 19.19M 2025-12
ALKERMES USD 334.02M 21.08M 2025-12
Alnylam Pharmaceuticals USD 883.96M 106.39M 2026-03
Amarin USD 126.83M 477K 2025-12
Amgen USD 9.14B 432M 2026-03
Baxter International USD 1.7B 310M 2026-03
Biogen USD 1.79B 76.6M 2026-03
BioMarin Pharmaceutical USD 903.91M 4.3M 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Coherus Biosciences USD 18.42M 232.08M 2025-12
Eli Lilly USD 21.18B 1.02B 2026-03
Fujifilm JPY 822.64B 36.85B 2025-12
Gilead Sciences USD 4.91B 182M 2025-12
Ironwood Pharmaceuticals USD 81.89M 5.68M 2024-12
Merck USD 11.78B 345M 2025-12
Myriad Genetics USD 115.3M 2.7M 2025-12
Pacira USD 125.64M 1.57M 2026-03
Perrigo USD 612.8M 31.6M 2025-12
Pfizer USD 15.84B 2.27B 2025-12
PTC Therapeutics USD 181.62M 21.45M 2025-12
Regeneron Pharmaceuticals USD 5.73B 10.1M 2026-03
Sarepta Therapeutics USD 398.23M 2.49M 2025-12
Teva Pharmaceutical Industries USD 3.39B 316M 2026-03
Vertex Pharmaceuticals USD 2B 56.7M 2026-03
Xencor USD 29.3M 7.49M 2025-12
Zoetis USD 1.59B 49M 2025-12